Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

The Lancet. Oncology

Volumn 15, Issue 10, 2014, Pages 1100-1108

  Stupp, Roger ^a   Hegi, Monika E ^b   Gorlia, Thierry ^a   Erridge, Sara C ^a   Perry, James ^a   Hong, Yong Kil ^a   Aldape, Kenneth D ^c   Lhermitte, Benoit ^b   Pietsch, Torsten ^a   Grujicic, Danica ^a   Steinbach, Joachim P eter ^a   Wick, Wolfgang ^b   Tarnawski, Rafał ^a   Nam, Do Hyun ^c   Hau, Peter ^a   Weyerbrock, Astrid ^a   Taphoorn, Martin J B ^a   Shen, Chiung Chyi ^a   Rao, Nalini ^b   Thurzo, László ^a   Herrlinger, Ulrich ^a   Gupta, Tejpal ^a   Kortmann, Rolf Dieter ^a   Adamska, Krystyna ^a   McBain, Catherine ^a   Brandes, Alba A ^a   Tonn, Joerg C hristian ^a   Schnell, Oliver ^a   Wiegel, Thomas ^c   Kim, Chae Yong ^a   Nabors, Louis B urt ^b   Reardon, David A ^b   van den Bent, Martin J ^a   Hicking, Christine ^a   Markivskyy, Andriy ^a   Picard, Martin ^c   Weller, Michael ^a   more..

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CILENGITIDE; DACARBAZINE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; SNAKE VENOM; TEMOZOLOMIDE; TUMOR SUPPRESSOR PROTEIN;

AGED; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; GENETICS; GLIOBLASTOMA; HUMAN; KAPLAN MEIER METHOD; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL; PROCEDURES; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SURVIVAL; TREATMENT OUTCOME; TUMOR INVASION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CONFIDENCE INTERVALS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EARLY DETECTION OF CANCER; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PATIENT SELECTION; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; REFERENCE VALUES; SNAKE VENOMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84908563697     PISSN: None     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70379-1     Document Type: Article

References (0)